Mike Havrilla's  Instablog

Allos Therapeutics, Inc. (ALTH)

Posts on ALTH by Mike Havrilla

• Access Pharma (OTC:ACCP): Deep Pipeline, Shallow Valuation

  July 14, 2009

• FDA Calendar Updates: KG, PTIE, DRRX, ALTH, TRIB, CBST, DYAX

  July 07, 2009

• Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await

  June 23, 2009

• BioMedReports FDA Calendar: Hot Summer Trades

  June 15, 2009

• FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO

  May 31, 2009

• FDA, Clinical Trial Updates: MAPP, CYTK, and HEB Post Big Gains

  May 26, 2009

• Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches

  May 17, 2009

• FDA, Clinical Trial Calendars: Prevacid Goes OTC, Swine Flu Test

  May 14, 2009

• Allos Therapeutics: Small-Cap Cancer Biotech with FDA Catalyst

  April 27, 2009

• FDA, Clinical Trial Calendar Updates: THOR, ALTH

  April 20, 2009

Posts on ALTH by other instabloggers

• Buyout Buzz at ASH Hematology Confab

  December 07, 2009 • Michael Becker

• Biotech Baker’s Dozen to Watch at Hematology Meeting

  November 29, 2009 • Michael Becker

• Movers and Shakers Include Flu Stocks SVA and BCRX

  October 14, 2009 • M. E. Garza

• Spectrum Pharmaceuticals: $50 Million Vote of Confidence or Cause for Concern

  September 18, 2009 • Justin M. Hall

• Spectrum Pharmaceuticals: Post Zevalin Approval Sales Should Ramp Up

  September 11, 2009 • Justin M. Hall